SIK2 and ovarian cancer: Our previous research also demonstrated that SIC-19, which targets SIK2, affects DNA HR repair and increases the vulnerability of ovarian cancer cells to PARP inhibitors by inhibiting phosphorylation at RAD50-Ser635.